Bausch Health Companies Inc. (BHC) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Multiple concerning factors at $5.64: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%).
Bausch Health is a global specialty pharma and medical device company with five segments: Salix (GI, led by Xifaxan at ~85% of Salix revenues), International, Solta Medical (aesthetic devices), Diversified, and ~88%-owned Bausch + Lomb (eye health). 2025 revenues were $10.27B;... Read more
Sell if holding. Multiple concerning factors at $5.64: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%). Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 6.3/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 89d clear, semi cycle peak clear). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXifaxan85%10-K Item 1: 'Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues'
- HIGHProductArestin95%10-K Item 1: 'Arestin®...represents approximately 95% of Dentistry revenues'
Material Events(8-K, last 90d)
- 2026-03-02Item 5.02LOWBausch Health amended 2023 PSU awards for CEO Thomas Appio and Seana Carson to settle in cash rather than stock on the March 3, 2026 vesting date. Routine compensatory arrangement modification; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $5.64: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%). Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $5.24. Score 6.3/10, moderate confidence.
Take-profit target: $6.59 (+16.9% upside). Prior stop was $5.24. Stop-loss: $5.24.
Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%); Leverage penalty (D/E 55.9): -1.5.
Bausch Health Companies Inc. trades at a P/E of N/A (forward 1.4). TrendMatrix value score: 9.5/10. Verdict: Sell.
9 analysts cover BHC with a consensus score of 2.4/5. Average price target: $8.
What does Bausch Health Companies Inc. do?Bausch Health is a global specialty pharma and medical device company with five segments: Salix (GI, led by Xifaxan at...
Bausch Health is a global specialty pharma and medical device company with five segments: Salix (GI, led by Xifaxan at ~85% of Salix revenues), International, Solta Medical (aesthetic devices), Diversified, and ~88%-owned Bausch + Lomb (eye health). 2025 revenues were $10.27B; Xifaxan generated $2.2B.